Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Cholesterol biogenesis is a PTEN-dependent actionable node for the treatment of endocrine therapy-refractory cancers.

Autor: Kaysudu I; Department of Molecular Biology and Genetics, Bilkent University, Ankara, Turkey., Gungul TB; Department of Molecular Biology and Genetics, Bilkent University, Ankara, Turkey., Atici S; Department of Molecular Biology and Genetics, Bilkent University, Ankara, Turkey., Yilmaz S; Department of Molecular Biology and Genetics, Bilkent University, Ankara, Turkey., Bayram E; Institute of Environmental Sciences, Bogazici University, Istanbul, Turkey., Guven G; Department of Biological Sciences, Middle East Technical University, Ankara, Turkey., Cizmecioglu NT; Department of Biological Sciences, Middle East Technical University, Ankara, Turkey., Sahin O; Department of Biochemistry and Molecular Biology, Hollings Cancer Center, MUSC, Charleston, South Carolina, USA., Yesiloz G; Institute of Materials Science and Nanotechnology, Bilkent University, Ankara, Turkey., Haznedaroglu BZ; Institute of Environmental Sciences, Bogazici University, Istanbul, Turkey., Cizmecioglu O; Department of Molecular Biology and Genetics, Bilkent University, Ankara, Turkey.; Department of Molecular Biology and Genetics, Faculty of Science, Bilkent University, Ankara, Turkey.

Publikováno v: Cancer science [Cancer Sci] 2023 Nov; Vol. 114 (11), pp. 4365-4375. Date of Electronic Publication: 2023 Sep 14.

Blocking PI3K p110β Attenuates Development of PTEN-Deficient Castration-Resistant Prostate Cancer.

Autor: Gao X; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts.; Department of Cell and Molecular Pharmacology and Experimental Therapeutics, Medical University of South Carolina, Charleston, South Carolina., Wang Y; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts., Ribeiro CF; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Masachusetts.; Department of Pathology, Harvard Medical School, Boston, Massachusetts., Manokaran C; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts., Chang H; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts., Von T; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts., Rodrigues S; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Masachusetts.; Department of Pathology, Harvard Medical School, Boston, Massachusetts., Cizmecioglu O; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts., Jia S; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Pathology, Harvard Medical School, Boston, Massachusetts., Korpal M; Oncology Disease Area, Novartis Institutes for BioMedical Research, Cambridge, Massachusetts., Korn JM; Oncology Disease Area, Novartis Institutes for BioMedical Research, Cambridge, Massachusetts., Wang Z; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts., Schmit F; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts., Jiang L; Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, Massachusetts., Pagliarini R; Oncology Disease Area, Novartis Institutes for BioMedical Research, Cambridge, Massachusetts., Yang Y; Oncology Disease Area, Novartis Institutes for BioMedical Research, Cambridge, Massachusetts., Sethi I; Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, Massachusetts., Signoretti S; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Masachusetts.; Department of Pathology, Harvard Medical School, Boston, Massachusetts., Yuan GC; Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, Massachusetts., Loda M; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Masachusetts.; Department of Pathology, Harvard Medical School, Boston, Massachusetts., Zhao JJ; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts., Roberts TM; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts.

Publikováno v: Molecular cancer research : MCR [Mol Cancer Res] 2022 May 04; Vol. 20 (5), pp. 673-685.

The Role of the Swollen State in Cell Proliferation.

Autor: Cohen BE; Universidad Central de Venezuela, Caracas, Venezuela. behorc@gmail.com.

Publikováno v: The Journal of membrane biology [J Membr Biol] 2024 Oct 31. Date of Electronic Publication: 2024 Oct 31.

The Roles of RAC1 and RAC1B in Colorectal Cancer and Their Potential Contribution to Cetuximab Resistance.

Autor: Wahoski, Claudia C.^1,2 (AUTHOR), Singh, Bhuminder² (AUTHOR) bhuminder.singh@vumc.org

Publikováno v: Cancers. Jul2024, Vol. 16 Issue 13, p2472. 25p.